Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · April 09, 2015

Adjuvant Ipilimumab Improves Recurrence-Free Survival in High-Risk Stage III Melanoma

The Lancet Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Adjuvant Ipilimumab Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (EORTC 18071): A Randomised, Double-Blind, Phase 3 Trial
Lancet Oncol 2015 Mar 31;[EPub Ahead of Print], AM Eggermont, V Chiarion-Sileni, JJ Grob, R Dummer, JD Wolchok, H Schmidt, O Hamid, C Robert, PA Ascierto, JM Richards, C Lebbé, V Ferraresi, M Smylie, JS Weber, M Maio, C Konto, A Hoos, V de Pril, RK Gurunath, G de Schaetzen, S Suciu, A Testori

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading